山东首例！山一大一附院实施前列腺癌PSMA靶向核素治疗

Core Insights - The first Lu-PSMA (Lutetium-177-PSMA) radioactive ligand therapy for prostate cancer was successfully completed at Shandong First Medical University First Affiliated Hospital, marking a significant advancement in precision treatment for metastatic castration-resistant prostate cancer (mCRPC) in Shandong province [1][3] - This innovative treatment approach utilizes prostate-specific membrane antigen (PSMA) as a molecular target, allowing for precise delivery of radioactive isotopes to tumor cells, thereby enhancing treatment efficacy and minimizing damage to surrounding healthy tissues [3] Treatment Details - The first patient treated was a 78-year-old male with advanced prostate cancer and multiple bone metastases, who had previously undergone various treatments including endocrine therapy and chemotherapy without success [1] - Following a comprehensive evaluation and PSMA-PET/CT scan, the medical team confirmed the patient's eligibility for Lu-PSMA therapy and developed a personalized treatment plan [1] Advantages of Lu-PSMA Therapy - Lu-PSMA therapy offers significant advantages over traditional chemotherapy and endocrine treatments, including higher clinical response rates and manageable side effects [3] - The radiation from Lu-PSMA therapy has a minimal penetration depth of only a few millimeters, resulting in reduced radiation exposure to normal tissues and a high safety profile [3] Institutional Strength - Shandong First Medical University First Affiliated Hospital is one of the first medical institutions in China to implement Lu-PSMA-617 therapy, showcasing its innovative capabilities and leadership in the field of cancer treatment [3]